Shattuck Labs reports positive Phase 1 data for SL-325, advances to Phase 2b trial in Q3 2026

Filed June 9, 2026 · Period ending June 8, 2026 · ~1 min read

Key Changes

• high

  Phase 1 trial of lead drug SL-325 showed favorable safety with no serious adverse events and very low immunogenicity (3.7% antidrug antibodies) in 72 healthy volunteers across multiple dose levels, supporting quarterly dosing potential.

  Item 8.01: Phase 1 Results verify on EDGAR →
• high

  Company will initiate RECEPTIVE-CD1 Phase 2b trial testing SL-325 in moderate-to-severe Crohn's disease in Q3 2026, enrolling ~174 patients with results expected in first half of 2028.

  Item 8.01: Phase 2b Trial verify on EDGAR →
• high

  Shattuck received exercise notices for ~50.6 million warrants (96% of August 2025 issuance), generating expected gross proceeds of ~$49.3 million to fund clinical programs.

  Item 8.01: Warrant Exercises verify on EDGAR →